Nanoform – Subcutaneously administered Nanotrastuzumab matches performance of Herceptin HYLECTA in minipig study
Nanoform Finland Plc | Press Release | February 12, 2026…
Nanoform Finland Plc’s change negotiations have ended
Nanoform Finland Plc | Company Release | February 05, 2026…
Nanoform – Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Nanoform Finland Plc | Company Release | January 29, 2026…
J.P. Morgan Healthcare Conference, San Francisco
Nanoform will be attending the J.P. Morgan Healthcare Conference in…
Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030
Nanoform Finland Plc | Inside Information | January 07, 2026…